A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant HIV.

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...

DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

"Time has stood still" for many who've been on complex regimens for decades ...

In a recent study published in EBioMedicine, a group of researchers determined the impact of nicotinamide mononucleotide (NMN) on Clusters of differentiation 4 + (CD4 +) Thymus cells (T cells) viz. T ...

Study dissects HIV reservoir clones that persist on ART, revealing how CD8+ T cells and resistance pathways could be harnessed for future cure strategies.

A review found that CD4/CD8 ratio could be used as a prognostic marker for mortality in patients with HIV, though future studies need to be done to confirm these findings. Clinical practices can ...

Real-world data show an ibalizumab-based regimen provides sustained virologic suppression in heavily treatment-experienced ...